@article{MTMT:34768357,
	title = {P-105 COLSTAR study: Safety data on the first cohort of patients from the safety lead-in part of the study},
	url = {https://m2.mtmt.hu/api/publication/34768357},
	author = {Ciardiello, F. and Yoshino, T. and Modest, D. and Martin, L. and Amellal, N. and Roby, L. and Prenen, H. and Kotani, D. and Horváth, Z. and Árkosy, Péter and Estfan, B. and Alanko, T. and Tabernero, J.},
	doi = {10.1016/j.annonc.2023.04.161},
	journal-iso = {ANN ONCOL},
	journal = {ANNALS OF ONCOLOGY},
	volume = {34},
	unique-id = {34768357},
	issn = {0923-7534},
	year = {2023},
	eissn = {1569-8041},
	pages = {S51-S51}
}

@article{MTMT:34738449,
	title = {1847P Monitoring of psychological state and quality of life during Simonton-training for oncologic patients},
	url = {https://m2.mtmt.hu/api/publication/34738449},
	author = {Harasztosi, P. and Lovey, J. and Nagy, Attila Csaba and Mailáth, Mónika},
	doi = {10.1016/j.annonc.2023.09.2798},
	journal-iso = {ANN ONCOL},
	journal = {ANNALS OF ONCOLOGY},
	volume = {34},
	unique-id = {34738449},
	issn = {0923-7534},
	year = {2023},
	eissn = {1569-8041},
	pages = {S1000-S1001},
	orcid-numbers = {Nagy, Attila Csaba/0000-0002-0554-7350}
}

@article{MTMT:34484647,
	title = {Vénás tromboembóliás szövődmények megelőzése és kezelése daganatos betegekben},
	url = {https://m2.mtmt.hu/api/publication/34484647},
	author = {Árokszállási, Anita and Horváth, Laura},
	doi = {10.26430/CHUNGARICA.2023.53.2.129},
	journal-iso = {CARDIOL HUNG},
	journal = {CARDIOLOGIA HUNGARICA},
	volume = {53},
	unique-id = {34484647},
	issn = {0133-5596},
	abstract = {A daganatos betegeknél a mélyvénás trombózis és a tüdőembólia a második leggyakoribb halálokot jelentik a daganatprogresszió után. Előfordulásuk folyamatosan növekedett az elmúlt évtizedekben és ez várhatóan így lesz a jövőben is. A vénás tromboembólia a morbiditás és mortalitás közvetlen növelésén túl egyes onkoterápiás szerek felfüggesztéséhez is vezethet, és ezáltal ronthatja az onkológiai kimenetelt. Érthető tehát, hogy a vénás tromboembóliák kockázatának felmérése, megelőzése és kezelése a szupportív onkoterápia elengedhetetlen része. Erre vonatkozóan számos klinikai vizsgálat és metaanalízis áll rendelkezésre, amelyek a jelenleg érvényes nemzetközi ajánlások alapjául szolgálnak. Az onkológiában a profilaktikus és terápiás antikoagulálásnak továbbra is elsődlegesen választandó szerei a kis molekulatömegű heparinok, de új szereplőként megjelentek a direkt aktivált X-es faktor gátló orális szerek is (apixaban, edoxaban, rivaroxaban). Egyelőre a terápiás és a szekunder profilaxisra rendelkezik az apixaban és a rivaroxaban törzskönyvi indikációval, a primer profilaxisra továbbra is a kis molekulatömegű heparinok javasolhatóak. A direkt trombingátló dabigatrannal nem történt randomizált kontrollált vizsgálat daganatos betegeknél a mélyvénás tromboembólia megelőzésére vagy kezelésére vonatkozóan. Munkánkban rövid áttekintést nyújtunk a daganatos betegek vénás tromboembóliás eseményeinek kezelésére és megelőzésére vonatkozó aktuális irányelvekről.},
	year = {2023},
	eissn = {1588-0230},
	pages = {129-133},
	orcid-numbers = {Horváth, Laura/0000-0001-8457-3647}
}

@article{MTMT:34397560,
	title = {Immunellenőrzőpont-gátlók a cervix- és endometriumcarcinoma kezelésének gyakorlatában - összefoglaló a Debreceni Egyetem Nőgyógyászati Onkológiai Tanszék betegeinek terápiás eredményeiről},
	url = {https://m2.mtmt.hu/api/publication/34397560},
	author = {Árokszállási, Anita and Molnár, Szabolcs and Damjanovich, Péter Gábor and Lukács, János and Kovács, Ilona and Molnár, Sarolta and Póka, Róbert and Hernádi, Zoltán and Lampé, Rudolf and Krasznai, Zoárd Tibor},
	journal-iso = {MAGYAR ONKOLÓGIA},
	journal = {MAGYAR ONKOLÓGIA},
	volume = {67},
	unique-id = {34397560},
	issn = {0025-0244},
	year = {2023},
	eissn = {2060-0399},
	pages = {9-10},
	orcid-numbers = {Lampé, Rudolf/0000-0002-8230-7692}
}

@article{MTMT:33802581,
	title = {Hepatocellularis carcinomás beteg sikeres májátültetése TACE- és sorafenibkezeléssel elért tumorméret-csökkentés után. Társszakmák sikeres együttműködése = Successful liver transplantation of a patient with hepatocellular carcinoma after reduction of tumour size by TACE and sorafenib treatment. Successful interdisciplinary collaboration},
	url = {https://m2.mtmt.hu/api/publication/33802581},
	author = {András, Csilla and Árokszállási, Anita and Csiki, Emese and Matolay, Orsolya and Árkosy, Péter and Jancsik, Viktor and Nemes, Balázs and Tóth, Judit and Varga, Enikő},
	doi = {10.33616/lam.33.0183},
	journal-iso = {LEGE ART MED},
	journal = {LEGE ARTIS MEDICINAE},
	volume = {33},
	unique-id = {33802581},
	issn = {0866-4811},
	abstract = {We present an instructive case of a long surviving female patient with primary liver cancer. She received transfusion during appendectomy, and 9 years later HCV positivity was diagnosed. That time the antiviral treatment did not succeed and liver cirrhosis developed. 24 years after the presumed HCV infection, hepatocellular carcinoma was diagnosed as a solitary tumour of the liver. Following two cycles of transarterial chemoembolization (TACE), during the exploratory laparotomy the tumour proved to be non-resectable be­cause of the malign hepatic hilar infiltration. Considering this, the multidisciplinary oncoteam recommended sorafenib treatment. The patient received sorafenib for 2.5 years that she well tolerated, and the tumour became smaller. After this, another TACE treatment was performed and the patient became suitable for liver transplantation. By the applied bridging therapy, after two unsuccessful donor calls, the liver transplantation was successfully performed. Long survival was finally achieved by the liver transplantation that solved both the cirrhosis and HCC conditions. By the newer direct-acting antiviral drugs, the patient became permanently HCV negative, and she is currently under hepatological care only. This case is a best example for possible tumour reduction and liver transplantation in inoperable hepatocellular carcinoma (HCC). We emphasise the importance of interdisciplinary collaboration while caring for patients with HCC. It is essential to delegate the patients to facilities where the full range of potentially relevant treatments, as well as the follow-up and care of the underlying liver disease are available.},
	keywords = {HCC; locoregional treatment; survival; liver transplantation; sorafenib; HCV; chemoembolisation (TACE)},
	year = {2023},
	eissn = {2063-4161},
	pages = {183-187}
}

@article{MTMT:33791187,
	title = {Áttétes vesedaganatos betegek kabozantinibterápiájának multicentrikus magyarországi eredményei},
	url = {https://m2.mtmt.hu/api/publication/33791187},
	author = {Maráz, Anikó and Nagyiványi, Krisztián András and Balogh, Ingrid and Bodoky, György and Mangel, László Csaba and Küronya, Zsófia and Géczi, Lajos and Torday, László and Dudás, Szilvia and Szűcs, Miklós and Nagy, Zsófia and Hornyák, Lajos and Zolcsák, Zita and Bassam, Ali and Kocsis, Judit and Keresztes, Tamás and Kullmann, Tamás and Máhr, Károly and Solymosi, Tibor and Rozsvai, Tímea and Szabó, Imre and Varga, Zoltán and Bíró, Krisztina},
	journal-iso = {MAGYAR ONKOLÓGIA},
	journal = {MAGYAR ONKOLÓGIA},
	volume = {67},
	unique-id = {33791187},
	issn = {0025-0244},
	abstract = {The aim of our analysis was to evaluate the efficacy of cabozantinib in patients with metastatic renal cell carcinoma. Cabozantinib therapy initiated between 01/01/2019 and 31/12/2022 was evaluated based on a retrospective review of data from 14 renal centers in Hungary. The starting dose was 60 or 40 mg. Physical examinations and laboratory tests were performed every 4 weeks and imaging studies 3-monthly. Tumor response was assessed according to RECIST 1.1, and toxicity according to NCI CTCAE 4.0. A total of 230 patient records were evaluated, 201 (87.4%) of them had clear cell RCC. Cabozantinib was administered as third, second and first-line treatment in 48.7%, 38.3% and <5% of cases, respectively. Dose reductions occurred in 62.6% and treatment interruption in 6.5%. Duration of therapy was 10.03 months, which was independent of dose reduction. Overall tumor response rate was 39.2% and clinical benefit was 82.8%. The duration of first-, second-, third- and fourth-line treatment was 11.47, 8.03, 11.57 and 10.13 months, respectively. Overall survival from the start of therapy was 22.0 months. Cabozantinib therapy in daily practice was more beneficial than according to registry study results. Dose reduction did not affect efficacy.},
	year = {2023},
	eissn = {2060-0399},
	pages = {73-83},
	orcid-numbers = {Maráz, Anikó/0000-0002-2018-8413; Bodoky, György/0000-0002-5659-2020; Küronya, Zsófia/0000-0001-8500-5924; Géczi, Lajos/0000-0001-7432-2043; Torday, László/0000-0002-2911-5499; Szűcs, Miklós/0000-0003-3576-8637; Varga, Zoltán/0000-0001-8537-6282; Bíró, Krisztina/0000-0002-2070-0608}
}

@article{MTMT:33688802,
	title = {Primer központi idegrendszeri daganatok ellátása : Összefoglaló klinikai onkológusok számára},
	url = {https://m2.mtmt.hu/api/publication/33688802},
	author = {Virga, József},
	journal-iso = {KLINIKAI ONKOLÓGIA},
	journal = {KLINIKAI ONKOLÓGIA},
	volume = {9},
	unique-id = {33688802},
	issn = {2064-5058},
	year = {2022},
	pages = {369-376}
}

@article{MTMT:32961748,
	title = {Breast Cancer Survivorship Programme: Follow-Up, Rehabilitation, Psychosocial Oncology Care. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer},
	url = {https://m2.mtmt.hu/api/publication/32961748},
	author = {Kahán, Zsuzsanna and Szanto, Istvan and Dudas, Rita and Kapitány, Zsuzsanna and Molnar, Maria and Koncz, Zsuzsa and Mailáth, Mónika},
	doi = {10.3389/pore.2022.1610391},
	journal-iso = {PATHOL ONCOL RES},
	journal = {PATHOLOGY AND ONCOLOGY RESEARCH},
	volume = {28},
	unique-id = {32961748},
	issn = {1219-4956},
	abstract = {Follow-up includes ongoing contact with and health education of the patient, surveillance and control of the adverse effects of surgery, oncological therapies or radiotherapy, screening of metachronous cancers, and comprehensive (physical, psychological and social) patient rehabilitation, which may be enhanced by a healthy lifestyle. Primary attention should be paid to early detection and, when needed, curative treatment of local/regional tumour recurrences. Similarly, with the hope of curative solution, it is important to recognize the entity of a low-mass and relatively indolent recurrence or metastasis (oligometastasis); however, there is still no need to investigate distant metastases by routine diagnostic imaging or assess tumour markers. Below there is a list of possible sources of support, with respect to adjuvant hormone therapy continued during long-term care, social support resources, pivotal points and professional opportunities for physical and mental rehabilitation. Individual solutions for specific issues (breast cancer risk/genetic mutation, pregnancy) are provided by constantly widening options. Ideally, a complex breast cancer survivorship programme is practised by a specially trained expert supported by a cooperative team of oncologists, surgeons, breast radiologists, social workers, physiotherapists, psycho-oncologists and psychiatrists. The approach of follow-up should be comprehensive and holistic.},
	keywords = {FOLLOW-UP; Healthy lifestyle; physical rehabilitation; Social rehabilitation; psychosocial oncology care; side-effect management},
	year = {2022},
	eissn = {1532-2807},
	orcid-numbers = {Kahán, Zsuzsanna/0000-0002-5021-8775; Koncz, Zsuzsa/0000-0003-1518-7253; Koncz, Zsuzsa/0000-0003-1518-7253}
}

@article{MTMT:32845313,
	title = {Cone beam CT verification of mask based immobilization of stereotactic radiotherapy treatments},
	url = {https://m2.mtmt.hu/api/publication/32845313},
	author = {Papp, Judit and Simon, Mihály and Csiki, Emese and Kovács, Árpád},
	journal-iso = {RADIOTHER ONCOL},
	journal = {RADIOTHERAPY AND ONCOLOGY},
	volume = {170},
	unique-id = {32845313},
	issn = {0167-8140},
	abstract = {ESTRO 41; 06 May 2022 - 10 May 2022 Copenhagen, Denmark},
	year = {2022},
	eissn = {1879-0887},
	pages = {S1629-S1630},
	orcid-numbers = {Papp, Judit/0000-0001-6066-6187; Kovács, Árpád/0000-0002-8469-5764}
}

@article{MTMT:32768234,
	title = {Hazai tapasztalatok metasztatikus kolorektális karcinóma bevacizumabbal kiegészített indukciós kemoterápiás kezelésével (AVACONT vizsgálat)},
	url = {https://m2.mtmt.hu/api/publication/32768234},
	author = {Landherr, László and Pintér, Tamás and Hornyák, Lajos and Révész, János and Máhr, Károly and Torday, László and András, Csilla and Erfán, József and Árkosy, Péter and Bodoky, György},
	journal-iso = {MAGYAR ONKOLÓGIA},
	journal = {MAGYAR ONKOLÓGIA},
	volume = {66},
	unique-id = {32768234},
	issn = {0025-0244},
	abstract = {The primary aim of AVACONT was to collect data in the course of routine oncological care from patients with metastatic colorectal cancer (mCRC) treated with bevacizumab supplemented fluoropyrimidine-based chemotherapy doublet in an open, multicentre, observational study in Hungary. Primary endpoint of the study was to determine progression-free survival (PFS). The Full Analysis Set (FAS) comprised 280 patients. Median PFS calculated from enrolment was 270 days in the FAS population. The metastatic involvement of the liver or more than one organ significantly decreased (250 and 245 days), while a clinical response achieved significantly increased (partial response: 404, complete response: 623 days) the mPFS calculated from enrolment. PFS calculated from the start of the first-line treatment was significantly decreased by the presence of mutant RAS gene (481 vs. 395 days). The results confirm the efficacy, known prognostic factors and safety profile of bevacizumab in combination with chemotherapy dosed during standard oncology care in Hungarian centres.},
	year = {2022},
	eissn = {2060-0399},
	pages = {11-19},
	orcid-numbers = {Torday, László/0000-0002-2911-5499; Bodoky, György/0000-0002-5659-2020}
}